PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-95.21%
Both companies show declining revenue. Martin Whitman would check for industry-wide issues.
31.39%
Cost growth above 1.5x TRVN's 4.35%. Michael Burry would check for structural cost disadvantages.
-116.81%
Both companies show declining gross profit. Martin Whitman would check industry conditions.
-451.18%
Margin decline while TRVN shows 100.00% expansion. Joel Greenblatt would examine competitive position.
6.71%
R&D growth while TRVN reduces spending. John Neff would investigate strategic advantage.
86.34%
G&A growth while TRVN reduces overhead. John Neff would investigate operational differences.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
29.34%
Operating expenses growth while TRVN reduces costs. John Neff would investigate differences.
29.34%
Total costs growth while TRVN reduces costs. John Neff would investigate differences.
-100.00%
Interest expense reduction while TRVN shows 1254.17% growth. Joel Greenblatt would examine advantage.
31.39%
D&A growth above 1.5x TRVN's 1.83%. Michael Burry would check for excessive investment.
-52.58%
EBITDA decline while TRVN shows 10.17% growth. Joel Greenblatt would examine position.
-3087.14%
EBITDA margin decline while TRVN shows 100.00% growth. Joel Greenblatt would examine position.
-52.01%
Operating income decline while TRVN shows 10.01% growth. Joel Greenblatt would examine position.
-3075.40%
Operating margin decline while TRVN shows 100.00% growth. Joel Greenblatt would examine position.
137.14%
Other expenses growth while TRVN reduces costs. John Neff would investigate differences.
-51.43%
Pre-tax income decline while TRVN shows 8.59% growth. Joel Greenblatt would examine position.
-3063.27%
Pre-tax margin decline while TRVN shows 100.00% growth. Joel Greenblatt would examine position.
100.00%
Tax expense growth less than half of TRVN's 647.89%. David Dodd would verify if advantage is sustainable.
-52.47%
Net income decline while TRVN shows 8.19% growth. Joel Greenblatt would examine position.
-3085.00%
Net margin decline while TRVN shows 100.00% growth. Joel Greenblatt would examine position.
-43.48%
EPS decline while TRVN shows 8.13% growth. Joel Greenblatt would examine position.
-43.48%
Diluted EPS decline while TRVN shows 8.13% growth. Joel Greenblatt would examine position.
7.17%
Share count reduction below 50% of TRVN's 0.00%. Michael Burry would check for concerns.
7.17%
Diluted share reduction below 50% of TRVN's 0.00%. Michael Burry would check for concerns.